Associated Papers
Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies.
Feichtenschlager V et al.
Communications Medicine, 2025
40473796 (PubMed )
Supplement: 43856_2025_932_MOESM3_ESM.xlsx › CRISPR
A deregulated m6A writer complex axis driven by BRD4 confers an epitranscriptomic vulnerability in combined DNA repair-targeted therapy.
Lu X et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
37782793 (PubMed )
Supplement: pnas.2304534120.sapp.pdf
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
31668570 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Select a paper to view details